深圳市海王英特龍生物技術股份有限公司（「本公司」）董事（「董事」）會（「董事會」）茲通告謹定於二零 二五年三月二十五日（星期二）上午十一時正於中華人民共和國（「中國」）廣東省深圳市南山區科技中三 路1號海王銀河科技大廈24樓會議室舉行董事會會議，以商討下列事項： 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 深圳市海王英特龍生物技術股份有限公司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （於中華人民共和國註冊成立的股份有限公司） （股份代號：8329） 董事會會議通告 深圳市海王英特龍生物技術股份有限公司 主席 張鋒 中國深圳市，二零二五年三月五日 * 僅供識別 1 1. 審議及批准本公司及其附屬公司截至二零二四年十二月三十一日止全年的經審核綜合年度業 績，以及批准將於香港聯合交易所有限公司（「聯交所」）GEM網站及本公司網站刊登的經審核綜 合年度業績的公佈稿； ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 深圳市海王英特龍生物技術股份有限公司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （在中華人民共和國註冊成立的股份有限公司） （股份代號：8329） 股東特別大會通告 承董事會命 茲通告深圳市海王英特龍生物技術股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）謹訂於 二零二四年十二月三十一日（星期二）上午十時正在中華人民共和國（「中國」）廣東省深圳市南山區科技 中三路1號海王銀河科技大廈24樓會議室舉行股東特別大會（「股東特別大會」），藉以考慮及酌情通過 下列決議案（無論有否修改）： 普通決議案 1 1. 「動議 (a) 批准、確認及追認本公司與深圳市海王易點藥醫藥有限公司於二零二四年十一月十五日訂 立之補充協議（「二零二三年補充易點藥代銷協議」）之形式及內容及其項下擬進行的所有交易 （二零二三年補充易點藥代銷協議註有「A」 ...

此乃要件 請即處理 閣下對本通函任何方面或應採取的行動如有任何疑問，應諮詢 閣下之持牌證券交易商或其他註 冊證券機構、銀行經理、律師、專業會計師或其他專業顧問尋求獨立意見。 閣下如已售出或轉讓名下所有深圳市海王英特龍生物技術股份有限公司的股份，應立即將本通 函連同隨附的代理人委任表格交予買主或承讓人或經手買賣或轉讓的銀行、持牌證券交易商或 其他證券註冊機構或其他代理人，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 深圳市海王英特龍生物技術股份有限公司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* 易點藥代銷協議之年度上限及提早終止； (2) 有關二零二四年易點藥代銷協議之 持續關連交易； (3) 有關續新二零二一年 藥業代銷協議之持續關連交易；及 (4) 股東特別大會通告 獨立董事委員會及 獨立股東之獨立財務顧問 （於中華人民共和國註冊成立的股份有限公司 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 深圳市海王英特龍生物技術股份有限公司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （於中華人民共和國註冊成立之股份有限公司） （股份代號：8329） (1)修訂有關二零二三年易點藥代銷協議之年度上限； (2)終止二零二三年易點藥代銷協議； (3)有關二零二四年易點藥代銷協議之持續關連交易； 及 (4)有關續新二零二一年藥業代銷協議之持續關連交易 獨立董事委員會及獨立股東之獨立財務顧問 1. 二零二三年易點藥代銷協議 茲提述本公司日期為二零二三年十二月二十八日有關二零二三年現有易點藥代銷協議之公 告。 自二零二三年現有易點藥代銷協議開始起，本公司出售之藥品、食品、保健食品及醫療設備 於中國市場廣受歡迎且銷量增長速度高於預期。於二零二四年一月一日起至二零二四年十月 三十一日止期間，二零二三年現有易點藥代銷協議項下之銷售總額約為人民幣9 ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 544,504,000, a decrease of 2% compared to RMB 555,531,000 in the same period of 2023[4]. - Gross profit for the reporting period was RMB 194,966,000, down 20.4% from RMB 245,316,000 in the previous year[4]. - Profit from operations increased to RMB 50,761,000, representing a 27.8% rise from RMB 39,721,000 in 2023[4]. - Profit before taxation was RMB 48,292,000, up 32.4% from RMB 36,474,000 in the same period last year[4]. - Net profit attributable to owners of the Company was RMB 37,907,000, an increase of 26.9% compared to RMB 29,881,000 in 2023[5]. - Basic and diluted earnings per share rose to RMB 2.26 cents, compared to RMB 1.78 cents in the previous year[5]. - Total comprehensive income for the period was RMB 41,254,000, up from RMB 31,090,000 in 2023[4]. - The company reported a profit of RMB 37,907,000 for the six months ended June 30, 2024, compared to RMB 29,881,000 for the same period in 2023, indicating a year-over-year increase of about 26.8%[9]. Assets and Liabilities - Current assets as of June 30, 2024, totaled RMB 930,660,000, compared to RMB 920,584,000 at the end of 2023[6]. - Non-current assets amounted to RMB 494,344,000, slightly down from RMB 495,062,000 at the end of 2023[6]. - As of June 30, 2024, net current assets increased to RMB 599,878,000 from RMB 554,404,000 at the end of 2023, representing an increase of approximately 8.2%[7]. - Total equity rose to RMB 1,057,436,000 as of June 30, 2024, compared to RMB 1,016,182,000 at the end of 2023, marking an increase of about 4.1%[8]. - The company generated RMB 21,217,000 from operating activities in the first half of 2024, compared to a cash outflow of RMB 52,320,000 in the same period of 2023, indicating a significant turnaround[10]. - Cash and cash equivalents at the end of the period were RMB 311,947,000, up from RMB 237,442,000 at the end of June 2023, representing a growth of approximately 31.4%[11]. - Interest-bearing borrowings decreased slightly to RMB 83,780,000 as of June 30, 2024, from RMB 85,417,000 at the end of 2023, a reduction of about 1.9%[7]. - The company’s total assets less current liabilities increased to RMB 1,094,222,000 from RMB 1,049,466,000, reflecting an increase of approximately 4.3%[7]. Revenue Breakdown - Revenue from manufacturing and selling of medicines and medical devices was RMB 295,150,000, down 27.5% from RMB 407,492,000 in 2023[17]. - Revenue from sales and distribution of medicines, healthcare products, and medical devices increased by 68.3% to RMB 249,354,000 from RMB 148,039,000 in 2023[17]. - Total revenue from manufacturing and selling medicines and medical devices was RMB 295,150,000 for the six months ended June 30, 2024, down from RMB 407,492,000 in 2023, reflecting a decrease of approximately 27.5%[30]. - Revenue from the sales of medicines and healthcare products decreased to RMB 423,917,000 for the six months ended June 30, 2024, down from RMB 446,340,000 in the same period of 2023, representing a decline of approximately 5.5%[29]. - Sales of medical devices increased to RMB 120,587,000 for the six months ended June 30, 2024, compared to RMB 109,191,000 in the same period of 2023, marking an increase of about 10.8%[29]. Expenses and Costs - The Group's total cost of inventories for the six months ended June 30, 2024, was RMB 338,296,000, compared to RMB 297,569,000 in 2023, reflecting an increase of approximately 13.7%[33]. - The Group's selling and distribution expenses were approximately RMB 82,983,000, representing a decrease of approximately 43.84% from approximately RMB 147,759,000 for the corresponding period of last year[134]. - The Group's other operating expenses and impairment/reversal on trade and other receivables, net amounted to approximately RMB 25,546,000, representing an increase of approximately 12.96% from approximately RMB 22,615,000 for the corresponding period of last year[135]. - Research and development costs increased to RMB 18,057,000 for the six months ended June 30, 2024, compared to RMB 14,518,000 in the same period of 2023, representing an increase of approximately 24.5%[35]. Taxation - The current tax expense for the six months ended June 30, 2024, was RMB 8,378,000, up from RMB 5,896,000 in 2023, indicating an increase of about 42.2%[38]. - The Group's tax rate for its subsidiaries in China is 25%, while three subsidiaries qualified for a reduced tax rate of 15% as "high-tech enterprises"[40]. Corporate Governance and Structure - The Company has adopted a code of conduct regarding securities transactions by Directors, ensuring compliance with GEM Listing Rules[158]. - The Company established an Audit Committee on 21 August 2005, responsible for reviewing annual reports and financial statements[162]. - The roles of the Chairman and General Manager are separate, with Mr. Zhang Feng serving as the current Chairman[162]. - The Company aims to enhance its corporate governance standards continuously[162]. Related Party Transactions - Related party transactions included sales of goods to Shenzhen Neptunus Pharmaceutical Company Limited totaling RMB 28,847,000 for the six months ended June 30, 2024, compared to RMB 30,336,000 in 2023[59]. - The company engaged in related party transactions, with total sales of goods to related parties amounting to RMB 2,489,000 from Jilin Neptunus Jiankang Technology Development Company Limited in 2024, down from RMB 4,233,000 in 2023, a decrease of 41.3%[79]. - The total amounts due from related parties reached RMB 54,123,000 as of June 30, 2024, compared to RMB 44,363,000 at December 31, 2023, reflecting a growth of 22%[114]. Shareholding and Capital Structure - As of June 30, 2024, Neptunus Bio-engineering held approximately 73.51% of the entire issued share capital of the Company, with 70.38% directly held and 3.13% indirectly held through Shenzhen Neptunus Oriental Investment Company Limited[152]. - Neptunus Bio-engineering directly owned 1,181,000,000 domestic shares, representing 94.33% of all domestic shares and approximately 70.38% of the Company's issued share capital[154]. - The Company has maintained a stable ownership structure with substantial shareholders holding significant percentages of the issued share capital[154]. Operational Developments - The Group operates two pharmaceutical production bases in Fuzhou and Beijing, with Fuzhou holding 366 approval documents for various medicines, including 207 listed in the National Medical Insurance Catalogue[123]. - The Group continues to invest in the research and development of new medicines and the consistency evaluation of generic medicines[124]. - Neptunus Zhongxin is undergoing operational transformation, including marketing model changes and organizational restructuring, to improve profitability[131].

1 深圳市海王英特龍生物技術股份有限公司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （於中華人民共和國註冊成立之股份有限公司） （股份代號：8329） 截至二零二四年六月三十日止六個月 之中期業績公告 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於 該等公司的潛在風險，並應經過審慎周詳的考慮後方可作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於聯交所主板買賣之證券承受較大的市場波動風險，同時無法保證在GEM買 賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公告的資料乃遵照聯交所的《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有關深圳市海王英特龍生物技術股份有限公司（「本公司」） 的資料。 ...

Financial Performance - For the three months ended March 31, 2024, the total profit and comprehensive income amounted to RMB 19,885,000, compared to RMB 19,198,000 for the same period in 2023, representing an increase of approximately 3.57%[3] - The operating profit for the same period was RMB 25,968,000, up from RMB 23,913,000 in 2023, indicating a growth of about 8.58%[7] - Basic and diluted earnings per share attributable to owners of the company increased to RMB 1.15 from RMB 0.97, reflecting a rise of approximately 18.56%[9] - The pre-tax profit for the period was RMB 24,894,000, compared to RMB 22,309,000 in the previous year, marking an increase of approximately 11.63%[27] Equity and Revenue - The company's total equity as of March 31, 2024, was RMB 1,036,067,000, compared to RMB 1,024,502,000 at the end of the previous quarter, showing a slight increase of about 1.54%[10] - The company's total revenue for the three months ended March 31, 2024, was RMB 280,329,000, down from RMB 299,718,000 in 2023, indicating a decrease of about 6.46%[25] Costs and Expenses - The financial costs decreased to RMB 1,074,000 from RMB 1,604,000, representing a reduction of approximately 33.00%[8] - Income tax expenses increased to RMB 5,009,000 from RMB 3,111,000, which is an increase of about 60.93%[13] Other Income and Non-controlling Interests - The net income attributable to non-controlling interests was RMB 585,000, down from RMB 2,934,000, reflecting a decrease of approximately 80.05%[21] - The company reported a net other income of RMB 2,507,000 for the period, compared to RMB 3,167,000 in the previous year, indicating a decline of about 20.83%[25]

Industry Overview - In 2023, the pharmaceutical industry experienced negative growth due to factors such as the end of the COVID-19 pandemic and centralized procurement policies, leading to a decline in prices of pharmaceutical products and high-value medical consumables [17]. - Sales of pandemic prevention medical devices, hygiene products, biological products, and chemical drugs recorded year-on-year decreases, while sales of Chinese medicines, non-pandemic prevention medical devices, and healthcare products showed an upward trend [17]. - The overall market conditions have prompted the company to adapt its strategies in response to the changing landscape of the pharmaceutical industry [17]. Business Operations - The Group's principal business includes research and development, manufacturing, and selling of medicines and medical devices, as well as the purchase and sales of healthcare food products [21][27][30]. - The Fuzhou Production Base holds 366 approval documents for Chinese and chemical medicines, with 235 varieties included in the National Medical Insurance Catalogue and 146 in the National Essential Drug List [28][31]. - The Beijing Production Base mainly produces chemical medicines and holds 137 approval documents, with 89 products included in the National Medical Insurance Catalogue [28][31]. - The Group has invested in the consistency evaluation of generic medicines and currently owns 35 patents for inventions, with four products having passed consistency evaluation [29][32]. - The Group is focusing on shifting products from low to high gross margins and expanding its consignment and contracted processing business model [21][24]. Financial Performance - The Group's total revenue for the Year was approximately RMB1,064,861,000, representing an increase of approximately 7.92% compared to the previous year [59]. - Approximately RMB576,679,000, accounting for approximately 54.16% of total revenue, was derived from the manufacturing and selling of medicines segment [59]. - Approximately RMB488,182,000, accounting for approximately 45.84% of total revenue, was derived from the sales and distribution of medicines and healthcare products segment [59]. - The Group's gross profit margin decreased to approximately 42%, down from approximately 45% in the previous year, a decline of approximately 3 percentage points [60]. - The Group's gross profit for the Year was approximately RMB447,511,000, representing an increase of approximately 0.76% compared to the previous year [61]. - Profit after tax decreased by approximately 77.24% to approximately RMB14,526,000, while profit attributable to owners decreased by approximately 55.60% to approximately RMB24,127,000 [70][75]. Operational Adjustments - The Group has adjusted its operational strategies in response to market conditions, including expanding the healthcare food product market and increasing the production of fine Chinese medicines [21][24]. - The Group plans to continue optimizing its business structure and improving governance and internal control systems [22][25]. - Neptunus Zhongxin faced challenges with sluggish sales and delayed new product introductions, resulting in a loss-making position, prompting operational adjustments for 2024 [39]. - The company plans to optimize pricing, channel strategies, and enhance budget control to achieve profitability in the upcoming year [41]. Employee and Management - The Group employed a total of 1,444 staff as of December 31, 2023, a decrease from 1,458 in the previous year [103]. - Staff costs, including directors' remuneration, amounted to approximately RMB148,985,000, a slight decrease from approximately RMB151,268,000 in the previous year [104]. - The management team includes experienced individuals with extensive backgrounds in the pharmaceutical industry, contributing to strategic decision-making [115][121][122]. - The company is focused on maintaining competitive employee compensation and benefits, with annual reviews based on performance [108]. - The management emphasizes the importance of employee performance in determining rewards and benefits, aligning with the company's overall business performance [107]. Strategic Focus - The Group aims to stabilize growth while controlling expenses and enhancing gross profit levels through multi-channel marketing and focusing on growth categories [22][25]. - The Group aims to strengthen the promotion of food supplements through a combination of various sales channels to drive sales growth [54]. - The company is actively involved in research and development of new products, leveraging over 30 years of experience in the biochemical and pharmaceutical industries [122]. - The company has a strategic focus on market expansion and enhancing its operational capabilities through experienced leadership [121]. Governance and Compliance - The Board did not recommend the payment of any dividend for the year, consistent with the previous year where no dividend was paid [109]. - The Company has no pre-emptive rights provisions in its articles of association [173]. - The remuneration for directors requires approval from the shareholders' meeting [200]. - The Group's management team includes experienced professionals with extensive backgrounds in finance and the pharmaceutical market [147][148]. Future Outlook - Fuyao Medical plans to introduce new products such as parenteral nutritional supplements in 2024 to broaden its business categories [46]. - The company is actively participating in national procurement alliances to seize market opportunities and drive sales of expiring varieties [36].

Financial Performance - The company's revenue for the year ended December 31, 2023, was RMB 1,064,861,000, representing an increase of 7.9% compared to RMB 986,691,000 in 2022[4] - Gross profit for the same period was RMB 447,511,000, slightly up from RMB 444,142,000, indicating a stable gross margin[4] - Operating profit decreased significantly to RMB 36,248,000 from RMB 89,293,000, reflecting a decline of 59.6% year-on-year[4] - The net profit attributable to the owners of the company was RMB 24,127,000, down from RMB 54,346,000, marking a decrease of 55.7%[4] - Basic and diluted earnings per share fell to RMB 1.44 from RMB 3.24, a decline of 55.6%[4] - The total reportable segment profit for 2023 was RMB 38,419,000, a decrease of 57.1% from RMB 89,599,000 in 2022[48] - The net profit after tax decreased by approximately 77.24%, from RMB 63,830,000 in the previous year to RMB 14,526,000 this year[92] Assets and Liabilities - Total assets as of December 31, 2023, were RMB 1,415,646,000, compared to RMB 1,448,230,000 in 2022, showing a decrease of 2.2%[5] - The total reportable segment assets increased to RMB 1,763,576,000 in 2023 from RMB 1,716,758,000 in 2022, reflecting a growth of 2.7%[48] - The total reportable segment liabilities rose to RMB 718,342,000 in 2023, compared to RMB 678,732,000 in 2022, an increase of 5.8%[48] - Accounts receivable increased to RMB 197,023,000 in 2023 from RMB 177,007,000 in 2022, representing an increase of about 11.3%[65] - The company reported a total of RMB 149,223,000 in accounts payable for 2023, up from RMB 114,003,000 in 2022, which is an increase of approximately 30.9%[68] - The company's current assets net value increased by approximately RMB 72,038,000 to RMB 554,404,000 compared to RMB 482,366,000 at the end of the previous year[95] Cash Flow and Equity - The company's cash and cash equivalents increased to RMB 372,206,000 from RMB 290,098,000, a rise of 28.3%[5] - The total equity attributable to the owners of the company increased to RMB 908,169,000 from RMB 884,042,000, reflecting a growth of 2.7%[6] - The company’s total receivables, including accounts receivable and notes receivable, amounted to RMB 332,954,000 in 2023, compared to RMB 341,968,000 in 2022, showing a slight decrease of about 2.7%[65] Research and Development - The company reported a total of RMB 46,203,000 in R&D expenses for 2023, up from RMB 28,723,000 in 2022, indicating a significant increase of 60.5%[56] - The group has invested in 35 invention patents and has passed consistency evaluations for 4 products, with several others in progress, including Vitamin B6 tablets awaiting approval[77][78] - New drug applications for the self-developed product Sildenafil Citrate orally disintegrating tablets and the sodium bicarbonate injection are expected to receive production approval in 2024[78] Market and Sales - Revenue from pharmaceutical production and sales was RMB 576,679,000, a decrease of 17% from RMB 694,840,000 in 2022[37] - Revenue from the sale and distribution of pharmaceuticals and health products increased to RMB 488,182,000, up 67% from RMB 291,851,000 in 2022[37] - Medical device sales contributed approximately RMB 210,674,000 to total revenue, compared to RMB 113,600,000 in 2022[37] - The Fuzhou subsidiary, Fuyuan Pharmaceutical, has seen significant growth in its medical device sales and plans to introduce new products in 2024 to ensure steady revenue growth[84] Corporate Governance and Compliance - The consolidated financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards and presented in Renminbi (RMB) as the functional currency[12] - The group has adopted new and revised Hong Kong Financial Reporting Standards effective from January 1, 2023, including HKFRS 17 on insurance contracts[15] - The financial statements for the year have been reviewed and confirmed by the audit committee and external auditors, ensuring compliance with applicable accounting standards[132] Employee and Administrative Expenses - Employee costs for the year ended December 31, 2023, amounted to RMB 44,641,000, compared to RMB 47,107,000 in 2022, reflecting a decrease of approximately 3.3%[17] - The company's administrative expenses were approximately RMB 90,433,000, a decrease of about 3.52% from RMB 93,733,000 in the previous year[90] - The company employed a total of 1,444 employees, a decrease from 1,458 employees in the previous year, with employee costs amounting to approximately RMB 148,985,000[108] Shareholder Information - Major shareholder Haiwang Biological held approximately 94.33% of the company's domestic shares, equating to 1,181,000,000 shares[120] - Haiwang Group, the controlling entity, held approximately 98.52% of the company's shares, totaling 1,233,464,500 shares[120] - The board of directors did not recommend any dividends for the current year, consistent with the previous year[110]

Financial Performance - For the nine months ended September 30, 2023, the company's revenue was RMB 823,180,000, representing an increase of 19.4% compared to RMB 689,399,000 for the same period in 2022[8]. - The gross profit for the nine months ended September 30, 2023, was RMB 358,983,000, up 17.9% from RMB 304,560,000 in the previous year[8]. - The profit from operations for the nine months ended September 30, 2023, was RMB 57,936,000, an increase of 11.6% compared to RMB 51,909,000 for the same period in 2022[8]. - For the nine months ended September 30, 2023, the profit before taxation increased to RMB 53,656,000, up 13.9% from RMB 47,335,000 in the same period of 2022[28]. - The total comprehensive income for the period was RMB 14,396,000, down from RMB 16,374,000 in the third quarter of 2022, representing a decline of 12.0%[28]. - The Company’s total comprehensive income for the nine months ended September 30, 2023, was RMB 45,486,000, significantly higher than RMB 34,209,000 in the same period of 2022, marking a growth of 32.9%[28]. - The earnings per share attributable to the owners of the Company for the period was RMB 0.93, unchanged from the same period in 2022[28]. - Profit attributable to the owners of the Company increased by approximately 26.81% from RMB 35,886,000 to RMB 45,506,000[93]. - The Group's net profit after tax was approximately RMB 45,486,000, an increase of about 32.96% compared to approximately RMB 34,209,000 in the previous year[127]. Expenses and Costs - Selling and distribution expenses for the nine months ended September 30, 2023, were RMB 215,651,000, which is an increase of 23.7% from RMB 174,350,000 in the previous year[8]. - Administrative expenses decreased to RMB 60,951,000 for the nine months ended September 30, 2023, down from RMB 64,360,000 in the same period of 2022, reflecting a reduction of 5.7%[8]. - Finance costs for the nine months ended September 30, 2023, were RMB 4,280,000, a decrease of 6.4% compared to RMB 4,574,000 for the same period in 2022[8]. - The Group's financial costs on bank loans decreased from RMB 4,541,000 in 2022 to RMB 4,149,000 in 2023 for the nine-month period, reflecting a reduction of approximately 9%[67]. - Other operating expenses increased by approximately 1.93% to RMB 32,380,000, primarily due to increased impairment on trade receivables[92]. Revenue Sources - Revenue is primarily derived from the production and sale of pharmaceuticals and the distribution of health products[19]. - Revenue from the manufacturing and selling of medicines segment was approximately RMB 591,245,000, accounting for about 71.82% of total revenue, with a year-on-year increase of approximately 21.87%[86]. - Revenue from the sales and distribution of medicines and healthcare products was RMB 231,935,000 for the nine months ended September 30, 2023, up 13.6% from RMB 204,242,000 in the prior year[167]. - The Group's revenue primarily arises from the manufacturing and selling of medicines and healthcare products, with a focus on oncology, cardiovascular, respiratory, digestive, and mental health therapeutic areas[76]. Assets and Equity - The retained earnings as of September 30, 2023, increased to RMB 344,316,000, compared to RMB 298,810,000 at the beginning of the year, reflecting a growth of 15.3%[29]. - The total equity as of September 30, 2023, was RMB 1,047,290,000, an increase from RMB 1,005,304,000 at the beginning of the year[29]. Compliance and Governance - The company is currently assessing the impact of new and amended HKFRSs on its financial results, which are unlikely to have a material impact on the financial statements[17]. - The company has adopted new and amended HKFRSs effective from January 1, 2023, which did not have a significant impact on the financial position[17]. - The company is committed to transparency and compliance with the GEM Listing Rules as part of its corporate governance[163]. - The Company has complied with the Corporate Governance Code during the Reporting Period and aims to enhance its governance standards[141]. Research and Development - Research and development costs for the three months ended September 30, 2023, amounted to RMB 9,144,000, up 16.8% from RMB 7,831,000 in the same period of 2022[41]. - The Group holds a total of 35 patents for inventions, with four products having passed the consistency evaluation[57]. - The Group's pharmaceutical subsidiary has received approval for Doxofylline Injection and Concentrated Sodium Potassium Magnesium Calcium Injection, enhancing its product portfolio[57]. Shareholder Information - The Group's controlling shareholder, Neptunus Bio-engineering, holds approximately 73.51% of the entire issued share capital of the Company, with 70.38% directly held and 3.13% indirectly held through Shenzhen Neptunus Oriental Investment Company Limited[131]. - The weighted average number of ordinary shares in issue for the three-month and nine-month periods ended September 30, 2023, was 1,678,000,000 shares, unchanged from 2022[73]. - The Company has not adopted any share option scheme or granted any options, convertible securities, or warrants as of September 30, 2023[145].